Pediatric perspective on pharmacogenomics. (November 2013)

• Record Type: Journal Article
• Authors: Stevens, Adam; De Leonibus, Chiara; Hanson, Daniel; Whatmore, Andrew; Murray, Philip; Donn, Rachelle; Meyer, Stefan; Chatelain, Pierre; Clayton, Peter
• Is Part Of: Pharmacogenomics. Volume 14:Number 15(2013)
• Page Start: 1889
• Page End: 1905
• Publication Date: 2013-11
• Subjects: adverse drug reactions -- pediatrics -- personalized medicine -- pharmacogenomics; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs.13.193
• Languages: English
• ISSNs: 1462-2416

Abstract

The advances in high-throughput genomic technologies have improved the understanding of disease pathophysiology and have allowed a better characterization of drug response and toxicity based on individual genetic make up. Pharmacogenomics is being recognized as a valid approach used to identify patients who are more likely to respond to medication, or those in whom there is a high probability of developing severe adverse drug reactions. An increasing number of pharmacogenomic studies are being published, most include only adults. A few studies have shown the impact of pharmacogenomics in pediatrics, highlighting a key difference between children and adults, which is the contribution of developmental changes to therapeutic responses across different age groups. This review focuses on pharmacogenomic research in pediatrics, providing examples from common pediatric conditions and emphasizing their developmental context.